HOOKIPA Pharma Inc. (HOOK)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
HOOK Insider Trading Activity
HOOK Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Insider Activity of HOOKIPA Pharma Inc.
Over the last 12 months, insiders at HOOKIPA Pharma Inc. have bought $0 and sold $0 worth of HOOKIPA Pharma Inc. stock.
On average, over the past 5 years, insiders at HOOKIPA Pharma Inc. have bought $38,445 and sold $5.35M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,000 shares for transaction amount of $5,075 was made by Kandera Reinhard (Chief Financial Officer) on 2023‑08‑21.
List of Insider Buy and Sell Transactions, HOOKIPA Pharma Inc.
| 2023-08-21 | Kandera Reinhard | Chief Financial Officer | 7,000 0.0091% | $0.72 | $5,075 | -8.21% | ||
| 2023-08-16 | Kandera Reinhard | Chief Financial Officer | 8,000 0.0103% | $0.71 | $5,712 | -6.65% | ||
| 2023-07-11 | Aldag Jorn | Chief Executive Officer | 5,000 0.007% | $0.83 | $4,142 | -14.57% | ||
| 2023-07-07 | Aldag Jorn | Chief Executive Officer | 5,000 0.0068% | $0.81 | $4,050 | -14.50% | ||
| 2023-07-05 | Aldag Jorn | Chief Executive Officer | 5,000 0.0071% | $0.89 | $4,450 | -18.79% | ||
| 2023-07-03 | Aldag Jorn | Chief Executive Officer | 5,000 0.0072% | $0.89 | $4,456 | -16.94% | ||
| 2023-06-30 | Kandera Reinhard | Chief Financial Officer | 12,000 0.0166% | $0.88 | $10,560 | -19.15% | ||
| 2021-12-21 | Sale | Matushansky Igor | Chief Medical Officer | 14,949 0.0457% | $2.49 | $37,223 | -37.90% | |
| 2021-04-21 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 328,620 0.9448% | $11.60 | $3.81M | -58.05% | |
| 2021-03-29 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 36,829 0.1234% | $13.67 | $503,570 | -54.96% | |
| 2021-03-26 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 35,171 0.1167% | $13.69 | $481,642 | -54.91% | |
| 2021-03-25 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 28,546 0.093% | $13.12 | $374,569 | -53.55% | |
| 2021-03-24 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 52,690 0.1841% | $13.70 | $721,616 | -52.05% | |
| 2021-03-23 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 40,000 0.1374% | $13.91 | $556,476 | -53.53% | |
| 2021-03-22 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 40,534 0.1369% | $14.54 | $589,263 | -55.71% | |
| 2021-03-19 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 166,230 0.5544% | $14.60 | $2.43M | -56.39% | |
| 2020-12-17 | Sale | Matushansky Igor | Chief Medical Officer | 27,979 0.1031% | $11.74 | $328,343 | -20.23% | |
| 2020-12-16 | Sale | Matushansky Igor | Chief Medical Officer | 380 0.0014% | $11.70 | $4,446 | -18.84% | |
| 2020-10-02 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 300 0.0011% | $10.00 | $3,000 | +13.55% | |
| 2020-09-15 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 41,597 0.1949% | $12.61 | $524,477 | +5.48% |
Insider Historical Profitability
| SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3177574 26.3501% | $3.97M | 1 | 12 | <0.0001% |
| Forbion Capital Fund II Cooperatief U.A. | 10 percent owner | 2494173 20.683% | $3.12M | 1 | 0 | <0.0001% |
| BAKER BROS. ADVISORS LP | 820729 6.8059% | $1.03M | 1 | 0 | <0.0001% | |
| Matushansky Igor | Chief Medical Officer | 80178 0.6649% | $100,222.50 | 0 | 6 | |
| Aldag Jorn | Chief Executive Officer | 71952 0.5967% | $89,940.00 | 4 | 0 | <0.0001% |
| Kandera Reinhard | Chief Financial Officer | 43092 0.3573% | $53,865.00 | 3 | 0 | <0.0001% |
| Lilja Anders | Sr. VP, Technical Development | 0 0% | $0 | 0 | 1 | |
| Orlinger Klaus | Sr. VP, Research | 0 0% | $0 | 0 | 3 |
Historical Insider Profitability vs. Competitors
$8,900,811 | 57 | -24.79% | $13.53M | |
$296,936 | 37 | -18.12% | $13.91M | |
$217,684 | 34 | 1.61% | $16.76M | |
$383,884 | 32 | -25.10% | $13.89M | |
$550,893 | 22 | -22.12% | $16.05M | |
$112,810,270 | 18 | -1.20% | $13.39M | |
$29,469,413 | 18 | 30.38% | $12.99M | |
$2,553,853 | 17 | 16.69% | $15.32M | |
$389,864 | 11 | 12.52% | $14.5M | |
$11,777,042 | 10 | -11.94% | $13.06M | |
HOOKIPA Pharma Inc. (HOOK) | $36,538,405 | 10 | -21.99% | $15.07M |
$38,247,728 | 10 | -10.97% | $13.9M | |
$70,584,874 | 10 | 3.97% | $15.37M | |
$189,648 | 9 | -52.20% | $15.87M | |
$2,891,537 | 8 | -39.31% | $13.82M | |
$2,060,158 | 5 | -21.35% | $15.87M | |
$31,190 | 2 | -14.18% | $15.2M | |
$245,940 | 2 | 31.12% | $16.58M | |
$5,512,500 | 1 | -7.91% | $15.96M |
HOOK Institutional Investors: Active Positions
| Increased Positions | 14 | +32.56% | 2M | +57.32% |
| Decreased Positions | 14 | -32.56% | 285,794 | -7.98% |
| New Positions | 8 | New | 2M | New |
| Sold Out Positions | 5 | Sold Out | 17,468 | Sold Out |
| Total Postitions | 43 | company.total | 5M | +49.34% |
HOOK Ownership Change vs Market
Institutional Investor Ownership
| Gilead Sciences, Inc. | $2,195.00 | 18.76% | 1.88M | +2M | New | 2024-12-31 |
| Baker Bros. Advisors Lp | $951.00 | 8.13% | 812,814 | 0 | 0% | 2024-12-31 |
| Siren, L.L.C. | $663.00 | 5.67% | 566,640 | 0 | 0% | 2024-12-31 |
| Knoll Capital Management, Llc | $583.00 | 4.99% | 498,625 | -53,113 | -9.63% | 2024-12-31 |
| Ecor1 Capital, Llc | $455.00 | 3.89% | 388,861 | -182,866 | -31.98% | 2024-12-31 |
| Fmr Llc | $414.00 | 3.54% | 353,794 | +12,318 | +3.61% | 2024-12-31 |
| Vanguard Group Inc | $249.00 | 2.13% | 213,222 | 0 | 0% | 2024-12-31 |
| Redmile Group, Llc | $124.00 | 1.06% | 106,376 | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $85.00 | 0.73% | 72,597 | -82 | -0.11% | 2024-12-31 |
| Acadian Asset Management Llc | $71.00 | 0.61% | 60,660 | -24,225 | -28.54% | 2024-12-31 |